Articles On Acrux (ASX:ACR)

Chrysos Corporation Ltd (ASX: C79) is an ASX industrials stock that has risen 67% year to date.  However, it hit a bit of a speed bump yesterday, falling 8%.  Last month, The Motley Fool's Leigh Grant covered in depth how its uniq...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

ASX closes up 1.03% to four-day high with strong performances in healthcare, materials and financials Gold hits another all-time high – of US$4211 per ounce Telix surges 16% after reporting robust September quarter revenue from its prostat...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Highlights Several ASX-listed companies demonstrate high levels of insider ownership, spanning healthcare, mining, and technology. Entities such as Clinuvel Pharmaceuticals (ASX:CUV), Develop Global (ASX:DVP), and Regis Healthcar...

Dimerix boss Dr Nina Webster to join Imagion Biosystems as non-executive director Webster has extensive experience with ASX healthcare companies and is also non-executive chair of SYNthesis BioVentures Appointment comes as Imagion prepares...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Genetic’s company-making US expansion proves harder than expected BTC Health makes a (literally) lifesaving sale The lessons from Sarepta’s billion-dollar FDA woes   Gut disease diagnostics provider Genetic Signatures (ASX:GSS) is finding...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Highlights ASX 200 poised for a positive open, reflecting cautious optimism amid global economic signals Firms such as ASX:ACR, ASX:CYC, and ASX:BBT show strong internal alignment and anticipated growth Sectoral growth expec...

Highlights ASX 200 sees upward momentum driven by IT and Financials, with Real Estate and Energy trailing. Noteworthy companies with high internal stakes show consistent revenue growth across varied sectors. Companies like A...

As a former bus driver, Dimerix (ASX:DXB) CEO Dr Nina Webster knows that the drug development journey is just as important as the destination when it comes to delivering value to shareholders. The therapeutic trip can be painfully long, esp...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Highlights Develop Global, Guzman y Gomez, and PYC Therapeutics feature among notable ASX growth stocks with high internal control. These companies operate in mining, food retail, and biotechnology sectors with diverse revenue so...

ASX tanks 4pc, worst drop since may 2020 Gold, copper, Bitcoin hammered in global rout Abacus Storage King bursts up after receiving buyout proposal    The ASX has taken a big hit on Monday, dropping by 4% as it marked the worst one-day l...

Highlights: Several ASX-listed companies have demonstrated high earnings expansion alongside substantial ownership from internal stakeholders. Businesses spanning sectors such as minerals, biotechnology, and consumer services exh...

Highlights: Several companies within the Australian market exhibit strong executive participation, reflecting confidence in their strategies. Businesses across various sectors, including resources, technology, and telecommunicati...

In the arvo session, the ASX held on to early gains… by a thread Nervy investor/trader eyes now await updates from the US on yet more inflation data and tariff announcements Amid the turmoil, wouldn’t you know it, gold stole the show   Af...

Highlights: Several ASX-listed companies demonstrate significant insider participation and strong earnings trajectories. Companies across various sectors continue expanding operations and strengthening market positions. An i...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlights ASX200 climbs steadily with positive market sentiment Growth companies benefit from substantial insider ownership Materials and IT sectors drive notable market performance The ASX200, the benchmark index representing le...

Pro Medicus signs $33m deal with University of Kentucky Memphasys’ RoXsta system advances antioxidant profiling potential Acrux launches 90-gram Dapsone Gel in US   These are today’s healthcare announcements from the ASX, with major progr...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Acrux Ltd (ASX:ACR) has been approved to begin U.S. commercialisation activities for its Nitroglycerin Ointment 0.4% targeting pain related to chronic anal fissures, with this marking the fourth Acrux product approved by the FDA. The oin...

ASX drops as tech stocks continue to slide Gold rebounds ahead of US inflation data South32 falls as Mozambique unrest disrupts production   The ASX extended its losses on Wednesday following the weak sentiment from Wall Street overnight....

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

  Michael Kotsanis – CEO & Managing Director – Acrux Limited (ASX:ACR) is a speciality pharma company with a successful track record of commercialising topically applied pharmaceuticals.

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX 200 down on Tuesday; energy and iron ore stocks rise BHP’s profit up 2pc, but dividend cut. Lovisa drops 12pc; Zip Co loses over 10pc despite strong revenue   The ASX traded cautiously following a mixed session on Wall Street. At the...

Acrux’s stock jumped after the US FDA approved its acne gel This new product addresses a market worth $37 million annually Island Pharma has begun patient screening for Phase 2 study on dengue fever   Acrux shares surge after US FDA appro...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

This week’s Bulls N’ Bears ASX Runner of the Week is… Regeneus Ltd. Its share price surged 220 per cent to join fellow movers and shakers Acrux Ltd and Perpetual Resources.

Specialty pharmaceutical company Acrux (ASX: ACR) and its partner TruPharma have launched a generic version of Aczone 5% Gel on the US market to treat acne vulgaris. Known as Dapsone 5% Gel, the prescription topical medicine was created to...

Acrux Ltd (ASX: ACR) shares are avoiding the market weakness and rocketing higher on Wednesday. In morning trade, the ASX healthcare stock was up as much as 110% to 9.9 cents. To put that into context, a $10,000 investment yesterday aftern...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

The S&P ASX 200 rose 1.19% in January to finish at a record high Energy was the winner with a 5% gain due to the turnaround in oil prices Health stocks up in January, including Singular Health Group and PharmAust After some up days an...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...